Clinical trials: Bladder Cancer
Cancer, Bladder, Surgery
3 Ultrasound Guided Plane Blocks for Perioperative Analgesia in Patients Undergoing Radical Cystectomy
Radical cystectomy is the gold standard treatment for muscle invasive bladder cancer as well as some T1 and non-invasive disease. It is a major operation with significant perioperative morbidity and complications.
- Conditions
- Cancer, Bladder, Surgery, Anesthesia, Analgesia
- Trial name
- NCT05278598
- Testing
- Erector Spinae Plane Block, Thoracic Paravertebral Plane Block, Quadratus Lumborum Plane Block
- Where
- Egypt
- Volunteers
- 120 people
- Sponsor
- Nazmy Edward Seif
Urinary Bladder Neoplasms
Prognostic Performance of a Chemogram in Patients With Bladder Cancer.
The aim of the study is to evaluate chemogram in patients with intermediate-grade superficial bladder cancer and patients with infiltrating bladder cancer, who are likely to be treated according to the standard procedure.
- Trial name
- CHEMOGRAM (NCT06403202)
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Lille Catholic University
Prostate Cancer, Urologic Cancer
The Man Van Project
National Health Service (NHS) England has commissioned The Royal Marsden Hospital NHS Foundation Trust to run a novel mobile clinical outreach service called 'Man Van' with the aim of enabling male patients' easy access to care…
- Conditions
- Prostate Cancer, Urologic Cancer, Urologic Diseases, Bladder Cancer
- Trial name
- MV (NCT06357416)
- Testing
- MV-POCT Sub-study, Main Man Van Group Sub-study (MV-Eco), MV-QualQ Sub-study
- Where
- United Kingdom
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- Royal Marsden NHS Foundation Trust
Advanced Solid Tumor, Cholangiocarcinoma
Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
This is a Phase Ib/II, multicenter, open-label study to evaluate the safety and preliminary efficacy of TT-00420 tablet, as monotherapy or in combination regimens, in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Cholangiocarcinoma, HER2-negative Breast Cancer, Triple Negative Breast Cancer
- Trial name
- NCT04742959
- Testing
- TT-00420, Nab-Paclitaxel
- Where
- 6 sites in United States
- Volunteers
- 203 people
- Sponsor
- TransThera Sciences (Nanjing), Inc.
Urinary Bladder Neoplasms, Bladder Cancer
A Study to Learn About the Effect of Avelumab First-Line Maintenance in Canadian People With Advanced Bladder Cancer
The purpose of this study is to learn about the safety and effects of the study medicine (called avelumab) for the treatment of advanced bladder cancer.
- Conditions
- Urinary Bladder Neoplasms, Bladder Cancer, Bladder Tumors, Urothelial Carcinoma
- Trial name
- NCT05699135
- Testing
- Avelumab first-line maintenance
- Where
- Canada
- Volunteers
- 150 people
- Sponsor
- Pfizer
Bladder Cancer
A Novel Application of 2% Lidocaine Injection for Male Rigid cycstoscopy-a Patient-blinded Randomised Trial
The goal of this clinical trial is to learn about a novel application of lidocaine injection in male patients who needs rigid cycstoscopy test.
- Trial name
- NCT06301308
- Testing
- Intraurethral lidocaine gel alone, Intraurethral lidocaine gel + lidocaine 2% injection, intraurethral lidocaine gel + liquid paraffinl
- Where
- China
- Sponsor
- Second Xiangya Hospital of Central South University
Bladder Cancer, Radiomics
The Efficacy of Radiomics to Predict Tumor Microenvironment Markers and Comprehensive Therapy for Bladder Cancer
The aim of this study was to develop an radiomic model based on CT images to evaluate markers of the bladder cancer microenvironment, such as TSR,TIL, and IP.
- Conditions
- Bladder Cancer, Radiomics, Immunotherapy
- Trial name
- NCT06381895
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
HER2-positive Breast Cancer, HER2-positive Gastric Cancer
PRS-343 in HER2-Positive Solid Tumors
A multi center, open-label, Phase 1 dose escalation study with expansion cohort is designed to determine the MTD, RP2D and dosing schedule of PRS-343 in patients with HER2+ advanced or metastatic solid tumors.
- Conditions
- HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Bladder Cancer, HER2-positive Solid Tumor
- Trial name
- NCT03330561
- Testing
- PRS-343
- Where
- 10 sites in United States
- Volunteers
- 85 people
- Sponsor
- Pieris Pharmaceuticals, Inc.
HER2-positive Breast Cancer, HER2-positive Gastric Cancer
PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors
A Phase 1b, open-label, dose escalation study of PRS-343 in combination with atezolizumab in patients with HER2-positive advanced or metastatic solid tumors.
- Conditions
- HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Bladder Cancer, HER2-positive Solid Tumor
- Trial name
- NCT03650348
- Testing
- PRS-343 in Combination with Atezolizumab
- Where
- 8 sites in United States
- Volunteers
- 41 people
- Sponsor
- Pieris Pharmaceuticals, Inc.
Bladder Cancer, BCG
Sequential Intravesical Gemcitabine and Docetaxel for Rescue Therapy in BCG Unresponsive Non-muscle Invasive Bladder Cancer Patients
Studies in the literature are limited both throughout Turkey and in general. For this reason, as a result of the study that we will create, it will provide us with information for bladder protective treatments in patients who do…
- Conditions
- Bladder Cancer, BCG, Gemcitabine, Docetaxel
- Trial name
- NCT06374914
- Testing
- Intravesical Solution
- Where
- Turkey (Türkiye)
- Volunteers
- 120 people
- Sponsor
- Dokuz Eylul University
Renal Cell Carcinoma (RCC), Urothelial Carcinoma
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
This is a Phase 1b/2, open-label, multicenter study of DSP-7888 Dosing Emulsion in combination with checkpoint inhibitors (nivolumab or pembrolizumab) in adult patients with solid tumors, that consists of 2 parts: dose search…
- Conditions
- Renal Cell Carcinoma (RCC), Urothelial Carcinoma, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer (PROC)
- Trial name
- NCT03311334
- Testing
- DSP-7888 Dosing Emulsion, Nivolumab, Pembrolizumab
- Where
- 19 sites in United States, Canada
- Volunteers
- 47 people
- Sponsor
- Sumitomo Pharma America, Inc.
Bladder Cancer
A Clinical Trial of Extraperitonealization for Prevention of Parastomal Hernia After Ileal Conduit
Many complications may occur after ileal conduit, with the incidence increasing with time after surgery. Nearly half of the complications are related to stoma and ureteroileal anastomosis.
- Trial name
- NCT03822234
- Testing
- Modified ileal conduit
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Sun Yat-sen University
Bladder Cancer Stage II
Radiogenomics of Muscle Invasive Bladder Cancer
Patients with suspected bladder tumor will undergo novel 4D MRI imaging along with single cell RNA sequencing in hopes of identifying a radiogenomic signature that can improve our staging of patients with muscle invasive bladder…
- Trial name
- NCT04806334
- Testing
- MRI imaging of the pelvis/bladder, genomic analysis of tumor
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Cedars-Sinai Medical Center
Muscle-invasive Bladder Cancer
Prediction of Therapeutic Response to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer Patients Using Spatial Transcriptomics
Although neoadjuvant chemotherapy in muscle-invasive bladder cancer has significantly improved oncological outcomes, approximately 50% of patients do not respond to neoadjuvant chemotherapy, which has adverse effects on patients…
- Trial name
- NCT06373055
- Testing
- neoadjuvant chemotherapy followed by radical cystectomy
- Where
- South Korea
- Volunteers
- 250 people
- Sponsor
- Yonsei University
Renal Cell Cancer, Melanoma
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
This is a first-in-human, Phase 1, open label, multicenter, multiple dose, dose escalation and expansion study intended to evaluate the safety, viral load kinetics and shedding, pharmacodynamic, and anti-tumor activity of…
- Conditions
- Renal Cell Cancer, Melanoma, Non-Small-Cell Lung Cancer, Hepatocellular Cancer
- Trial name
- NCT05061537
- Testing
- PF-07263689, Sasanlimab
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- Pfizer
Muscle-invasive Bladder Cancer, Artificial Intelligence
Multi-parametric MRI in Patients of Bladder Cancer
Accurate preoperative detection of muscle-invasive bladder cancer remains a clinical challenge. The investigators aimed to develop and validate a knowledge-guided causal diagnostic network for the detection of muscle-invasive…
- Trial name
- NCT06362330
- Testing
- magnetic resonance imaging
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Bladder Cancer, Bladder Cancer Stage I
The Impact of Neoadjuvant Chemotherapy on Survival Outcomes in Patients With Variant Histologies Bladder Cancer Who Underwent Radical Cystectomy
The World Health Organization 2016 bladder tumor classification reported that the diagnosis of variant histology has increased from 6% to 33% in the last 2 decades, and there is an increasing interest in investigating the effects…
- Conditions
- Bladder Cancer, Bladder Cancer Stage I, Bladder Cancer Stage II
- Trial name
- NCT06358599
- Testing
- Cisplatin
- Where
- Turkey (Türkiye)
- Volunteers
- 221 people
- Sponsor
- Ankara Etlik City Hospital
Non-Small Cell Lung Cancer, Urothelial Cancer
A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)
This is a Phase 2 study to evaluate the safety and efficacy of avelumab in combination with axitinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior platinum…
- Trial name
- NCT03472560
- Testing
- Avelumab (MSB0010718C), Axitinib (AG-013736)
- Where
- 39 sites in United States, Hungary and 6 more
- Volunteers
- 61 people
- Sponsor
- Pfizer
Bladder Cancer
Pre-operative Immuno-Nutrition in Radical Cystectomy
This study will evaluate the effect of preoperative oral immunonutrition on postoperative complications in patients undergoing radical cystectomy for bladder cancer.
- Trial name
- INu-RC (NCT06355518)
- Testing
- Immunonutrition, Standard Oral Nutritional Supplement
- Where
- 2 sites in Italy
- Volunteers
- 260 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Microbiome, Bladder Cancer
Role of Microbiome in BCG Responsiveness Prediction
Our primary aim is to investigate the use of microbial profile from the bladder and the feces of NMIBC patients as a predicting tool for therapy response prior to BCG administration.
- Trial name
- SILENTEMPIRE (NCT05204199)
- Where
- 5 sites in Switzerland
- Volunteers
- 120 people
- Sponsor
- Cédric Poyet